Get the Stockscreener App
35.39
0.43%
0.15
Vaxcyte Inc stock is traded at $35.39, with a volume of 1.94M.
It is up +0.43% in the last 24 hours and up +5.05% over the past month.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
See More
Previous Close:
$35.24
Open:
$35.75
24h Volume:
1.94M
Relative Volume:
0.99
Market Cap:
$4.25B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-7.6935
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
+7.50%
1M Performance:
+5.05%
6M Performance:
-67.01%
1Y Performance:
-45.17%
1-Day Range:
$34.90
$36.71
1-Week Range:
$31.27
$36.71
52-Week Range:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
35.39 | 4.25B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaxcyte appoints new independent director - Investing.com Australia
Vaxcyte appoints new independent director By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Welcomes Former Sanofi CEO to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board - TipRanks
Vaxcyte adds former Sanofi CEO to its board - Investing.com
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - GlobeNewswire
Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? - Yahoo Finance
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
James T. Wassil ’99G ’05G of Vaxcyte, Inc. Named Lehigh’s 2025 Graduate Commencement and Doctoral Hooding Ceremony Speaker - Lehigh University
Vaxcyte (PCVX) Gains Attention with Overweight Rating Amid Marke - GuruFocus
Vaxcyte (PCVX) Sees Surge in Investor Interest Amid Biotech Buzz - GuruFocus
Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options - Nasdaq
TD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX) - The Globe and Mail
Vaxcyte (PCVX) Stock Price, News & Analysis - MarketBeat
When the Price of (PCVX) Talks, People Listen - news.stocktradersdaily.com
2 ‘Strong Buy’ Growth Stocks That Could Gain More Than 340% - The Globe and Mail
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason - MSN
Vaxcyte Stock Plummets: What’s Next? - timothysykes.com
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential - Insider Monkey
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges - Investing.com India
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges By Investing.com - Investing.com South Africa
Vaxcyte (NASDAQ:PCVX) Price Target Lowered to $137.00 at Bank of America - MarketBeat
InvestingPro Fair Value model correctly predicted Vaxcyte’s decline By Investing.com - Investing.com UK
Vaxcyte (NASDAQ:PCVX) Given New $137.00 Price Target at Bank of America - Defense World
(PCVX) Investment Analysis - news.stocktradersdaily.com
Vaxcyte (PCVX) Stock Falls 45% Despite Positive Vaccine Trial Re - GuruFocus
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI - Yahoo Finance
BofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’ - TipRanks
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Vaxcyte stock sinks despite Phase II IPD vaccine trial success - Yahoo Finance
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Vaxcyte’s Promising Vaccine Potential and Market Expansion Drive Buy Rating - TipRanks
Goldman Sachs cuts Vaxcyte stock price target to $100 - Investing.com
Goldman Sachs cuts Vaxcyte stock price target to $100 By Investing.com - Investing.com UK
Vaxcyte’s Strong Phase 2 Data and Future Prospects Justify Buy Rating Despite Market Overreaction - TipRanks
Vaxcyte price target lowered to $90 from $140 at Needham - MSN
Vaxcyte sights set on next results after ‘big moment’ with PCV - BioWorld MedTech
Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (NASDAQ:PCVX) - Seeking Alpha
Sector Update: Health Care Stocks Higher Late Afternoon - MarketScreener
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (NASDAQ:PCVX) - Seeking Alpha
Jefferies maintains Buy on Vaxcyte stock, price target at $146 By Investing.com - Investing.com Canada
Vaxcyte’s VAX-24: Promising Infant Vaccine Results Amidst Investor Concerns - TipRanks
Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials - TipRanks
Vaxcyte falls as pneumococcal vaccine data fails to meet lofty investor expectations - TradingView
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vaxcyte Inc Stock (PCVX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):